CL2016001231A1 - Compuestos de inhibidor de autotaxina - Google Patents
Compuestos de inhibidor de autotaxinaInfo
- Publication number
- CL2016001231A1 CL2016001231A1 CL2016001231A CL2016001231A CL2016001231A1 CL 2016001231 A1 CL2016001231 A1 CL 2016001231A1 CL 2016001231 A CL2016001231 A CL 2016001231A CL 2016001231 A CL2016001231 A CL 2016001231A CL 2016001231 A1 CL2016001231 A1 CL 2016001231A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor compounds
- autotaxin inhibitor
- autotaxin
- autotaxine
- fibrosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Abstract
COMPUESTOS HETEROCICLICOS NITROGENADOS SUSTITUIDOS, INHIBIDORES DE AUTOTAXINA; PROCEDIMIENTO DE PREPARACION; COMPOSICION FARMACEUTICA; COMBINACION FARMACEUTICA; USO EN EL TRATAMIENTO O PREVENCION DE CANCER Y FIBROSIS ENTRE OTRAS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361907965P | 2013-11-22 | 2013-11-22 | |
US201462038121P | 2014-08-15 | 2014-08-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2016001231A1 true CL2016001231A1 (es) | 2017-01-20 |
Family
ID=53180152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2016001231A CL2016001231A1 (es) | 2013-11-22 | 2016-05-20 | Compuestos de inhibidor de autotaxina |
Country Status (31)
Country | Link |
---|---|
US (6) | US9334261B2 (es) |
EP (2) | EP3071561B1 (es) |
JP (1) | JP6501367B2 (es) |
KR (2) | KR102515248B1 (es) |
CN (2) | CN105793253B (es) |
AU (2) | AU2014352888B2 (es) |
BR (1) | BR112016010220B1 (es) |
CA (1) | CA2930737C (es) |
CL (1) | CL2016001231A1 (es) |
CR (2) | CR20190394A (es) |
CY (1) | CY1124407T1 (es) |
DK (1) | DK3071561T3 (es) |
EA (1) | EA030068B1 (es) |
ES (1) | ES2875899T3 (es) |
HK (1) | HK1226075A1 (es) |
HR (1) | HRP20210957T1 (es) |
HU (1) | HUE055213T2 (es) |
IL (2) | IL245383B (es) |
LT (1) | LT3071561T (es) |
MX (2) | MX2016006623A (es) |
MY (1) | MY182095A (es) |
NI (1) | NI201600071A (es) |
NZ (1) | NZ720478A (es) |
PE (1) | PE20160654A1 (es) |
PH (1) | PH12016500862B1 (es) |
PL (1) | PL3071561T3 (es) |
PT (1) | PT3071561T (es) |
RS (1) | RS62027B1 (es) |
SI (1) | SI3071561T1 (es) |
WO (1) | WO2015077503A1 (es) |
ZA (2) | ZA201603083B (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201407534PA (en) | 2012-06-13 | 2014-12-30 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
IN2015DN00960A (es) | 2012-09-25 | 2015-06-12 | Hoffmann La Roche | |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
CN105793253B (zh) | 2013-11-22 | 2019-08-23 | 法玛克亚公司 | 自分泌运动因子抑制剂化合物 |
BR112016010221A2 (pt) | 2013-11-22 | 2018-05-02 | Pharmakea Inc | inibidores tetracíclicos de autotaxina. |
MY187449A (en) | 2013-11-26 | 2021-09-22 | Hoffmann La Roche | New octahydro-cyclobuta [1,2-c;3,4-c']dipyrrol-2-yl |
HUE046820T2 (hu) | 2014-03-26 | 2020-03-30 | Hoffmann La Roche | Biciklusos vegyületek autotaxin (ATX) és lizofoszfatidsav (LPA) termelésgátlókként |
JP6554481B2 (ja) | 2014-03-26 | 2019-07-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | オートタキシン(atx)及びリゾホスファチジン酸(lpa)産生の阻害剤としての縮合[1,4]ジアゼピン化合物 |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
AU2016268250B2 (en) * | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
CR20180058A (es) | 2015-09-04 | 2018-02-26 | Hoffmann La Roche | Nuevos derivados de fenoximetilo |
MX2018001890A (es) | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
KR20180054830A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 오토탁신(atx) 억제제로서의 이환형 화합물 |
CN107922415B (zh) | 2015-09-24 | 2022-04-15 | 豪夫迈·罗氏有限公司 | 新的作为双重atx/ca抑制剂的二环化合物 |
US11000142B2 (en) | 2016-12-06 | 2021-05-11 | John Joseph Girard | Flexible floor mat incorporating LED lighting |
WO2018167113A1 (en) | 2017-03-16 | 2018-09-20 | F. Hoffmann-La Roche Ag | New bicyclic compounds as atx inhibitors |
CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
AU2018323470A1 (en) | 2017-08-28 | 2020-03-19 | Angiex, Inc. | Anti-TM4SF1 antibodies and methods of using same |
WO2023215196A1 (en) * | 2022-05-03 | 2023-11-09 | Sabre Therapeutics Llc | Polymorphic and salt forms of the autotaxin inhibitor cudetaxestat |
CN116239577A (zh) * | 2023-03-27 | 2023-06-09 | 沈阳药科大学 | 一种制备Cudetaxestat的方法 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5210574A (en) | 1991-03-08 | 1993-05-11 | Mita Industrial Co., Ltd. | Photosensitive drum body-mounting mechanism including a drive coupling member with a coupling protrusion adapted to bite into the inner surface of the mechanism's photosensitive drum |
US5186522A (en) | 1991-09-24 | 1993-02-16 | Midland Brake, Inc. | Air dryer purge line |
WO1994011661A1 (en) | 1992-11-10 | 1994-05-26 | Caterpillar Inc. | Solenoid valve assembly |
US5407368A (en) | 1992-12-15 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Electrode connector |
US5761473A (en) | 1993-01-08 | 1998-06-02 | International Business Machines Corporation | Method and system for increased instruction synchronization efficiency in a superscalar processsor system utilizing partial data dependency interlocking |
US5564949A (en) | 1995-01-05 | 1996-10-15 | Thomas & Betts Corporation | Shielded compact data connector |
JP2664048B2 (ja) | 1995-03-27 | 1997-10-15 | 科学技術庁金属材料技術研究所長 | 六フッ化二ケイ素の合成法 |
GB9514473D0 (en) | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
EP1284728A4 (en) | 1999-10-22 | 2004-05-19 | Merck & Co Inc | MEDICINES FOR TREATING ADDICTIC ADDICTION |
US6890933B1 (en) | 2000-02-24 | 2005-05-10 | President And Fellows Of Harvard College | Kinesin inhibitors |
AU2002213421A1 (en) | 2000-10-03 | 2002-04-15 | Lilly Icos Llc | Condensed pyridoindole derivatives |
AR035857A1 (es) | 2001-04-11 | 2004-07-21 | Novirio Pharmaceuticals Ltd | Fenilindoles; sus composiciones farmaceuticas y sus usos |
JP4141954B2 (ja) | 2001-09-27 | 2008-08-27 | エフ.ホフマン−ラ ロシュ アーゲー | Coxiiインヒビターとしてのインドール誘導体 |
US7528165B2 (en) | 2001-12-13 | 2009-05-05 | National Health Research Institutes | Indole compounds |
JP4340232B2 (ja) | 2002-08-29 | 2009-10-07 | メルク エンド カムパニー インコーポレーテッド | 抗糖尿病活性を有するインドール類 |
WO2004020409A1 (en) | 2002-08-29 | 2004-03-11 | Merck & Co., Inc. | Indoles having anti-diabetic activity |
JP4575920B2 (ja) | 2003-05-19 | 2010-11-04 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
ES2303960T3 (es) | 2003-12-23 | 2008-09-01 | H. Lundbeck A/S | Derivados de 2-(1h-indolilsulfanil)-bencilamina como isrs. |
CN1957117A (zh) | 2004-05-19 | 2007-05-02 | 住友电气工业株式会社 | Ⅲ族氮化物半导体晶体和其制造方法以及ⅲ族氮化物半导体器件 |
KR101141650B1 (ko) | 2004-09-30 | 2012-05-17 | 엘지전자 주식회사 | 매체접속제어 계층에서의 데이터 처리 방법 및 이동통신용단말 |
WO2006041961A1 (en) | 2004-10-05 | 2006-04-20 | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES | Arylthioindole tubulin polymerization inhibitors and methods of treating or preventing cancer using same |
US20080319044A1 (en) | 2004-11-01 | 2008-12-25 | Nuada, Llc | Compounds and Methods of Use Thereof |
WO2007134169A2 (en) | 2006-05-10 | 2007-11-22 | Nuada, Llc | Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof |
US20060270634A1 (en) | 2005-05-06 | 2006-11-30 | Miller Duane D | Acetal phosphate-derived LPA mimics, PPARgamma activators, and autotaxin inhibitors |
AR054394A1 (es) | 2005-06-17 | 2007-06-20 | Lundbeck & Co As H | Derivados de 2- (1h-indolilsulfanil)-aril amina |
US7921385B2 (en) | 2005-10-03 | 2011-04-05 | Luminescent Technologies Inc. | Mask-pattern determination using topology types |
EP1962838B1 (en) | 2005-12-19 | 2011-09-28 | GlaxoSmithKline LLC | Farnesoid x receptor agonists |
WO2008157361A1 (en) | 2007-06-15 | 2008-12-24 | University Of Utah Research Foundation | α-CHLORO AND α-BROMO PHOSPHONATE ANALOGS OF LYSOPHOSPHATIDIC ACID AND METHODS OF MAKING AND USING THEREOF |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
DE102007047735A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Thiazolderivate |
DE102007047738A1 (de) | 2007-10-05 | 2009-04-09 | Merck Patent Gmbh | Imidazolderivate |
US8268891B1 (en) | 2007-11-13 | 2012-09-18 | University Of Memphis Research Foundation | Autotaxin inhibitors |
US8378100B2 (en) | 2008-01-09 | 2013-02-19 | University Of Virginia Patent Foundation | Phosphonate derivatives as autotaxin inhibitors |
WO2009151644A2 (en) | 2008-06-13 | 2009-12-17 | Yale University | Small molecule inhibitors of autotaxin methods of use |
WO2010040080A1 (en) | 2008-10-03 | 2010-04-08 | Abby Louise Parrill-Baker | Mechanism-based inactivators of autotaxin |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
CN102216299B (zh) | 2008-12-01 | 2015-02-11 | 默克专利有限公司 | 作为自体毒素抑制剂的2,5-二氨基取代的吡啶并[4,3-d]嘧啶化合物 |
EA201101396A1 (ru) * | 2009-04-02 | 2012-09-28 | Мерк Патент Гмбх | Ингибиторы аутотаксина |
CN102369186B (zh) | 2009-04-02 | 2014-07-09 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的哌啶和哌嗪衍生物 |
ES2527788T3 (es) * | 2009-04-02 | 2015-01-30 | Merck Patent Gmbh | Compuestos heterocíclicos como inhibidores de autotaxina |
US8445200B2 (en) | 2009-04-15 | 2013-05-21 | The Regents Of The University Of California | Genotoxicity as a biomarker for inflammation |
KR20120034649A (ko) | 2009-05-11 | 2012-04-12 | 버그 바이오시스템즈, 엘엘씨 | 환경대사적 전환인자(조효소 q10)를 사용한 질환의 치료 방법 |
CN102459598B (zh) | 2009-05-20 | 2016-06-01 | Eth苏黎世公司 | 用于代谢紊乱的靶向微小rna |
WO2011002918A1 (en) | 2009-06-30 | 2011-01-06 | The University Of Memphis Research Foundation | Novel diverse lead compound autotaxin inhibitors |
DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
DE102009049211A1 (de) | 2009-10-13 | 2011-04-28 | Merck Patent Gmbh | Sulfoxide |
WO2011049433A1 (en) | 2009-10-23 | 2011-04-28 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Diagnosis and treatment of pruritis |
WO2011053597A1 (en) | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
US8497371B2 (en) | 2009-10-26 | 2013-07-30 | University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
WO2011103430A1 (en) | 2010-02-19 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
CA2794211A1 (en) * | 2010-03-26 | 2011-09-29 | Wolfgang Staehle | Benzonaphthyridinamines as autotaxin inhibitors |
US20130116171A1 (en) | 2010-04-16 | 2013-05-09 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf |
EP2606031B1 (en) * | 2010-08-20 | 2017-09-27 | Amira Pharmaceuticals, Inc. | Autotaxin inhibitors and uses thereof |
US8771696B2 (en) | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
US8673882B2 (en) | 2011-01-20 | 2014-03-18 | University Of Tennessee Research Foundation | Inhibitors of autotaxin |
IN2013MN01699A (es) | 2011-02-18 | 2015-06-12 | Medivation Technologies Inc | |
WO2012112964A2 (en) | 2011-02-18 | 2012-08-23 | Medivation Technologies, Inc. | PYRIDO[4,3-b]INDOLE AND PYRIDO[3,4-b]INDOLE DERIVATIVES AND METHODS OF USE |
EP2685976B1 (en) | 2011-03-17 | 2017-12-27 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Quinolone analogs for treating autoimmune diseases |
US9260416B2 (en) | 2011-05-27 | 2016-02-16 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
GB2494154B (en) | 2011-08-31 | 2017-11-29 | Metaswitch Networks Ltd | Conditional telecommunications |
WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
ES2648901T3 (es) | 2011-10-28 | 2018-01-08 | Inhibitaxin Limited | Derivados de piridazina útiles en terapia |
JP2013129632A (ja) | 2011-12-22 | 2013-07-04 | Ono Pharmaceut Co Ltd | Enpp2阻害化合物 |
US20130270634A1 (en) | 2012-04-12 | 2013-10-17 | Richtek Technology Corporation | High voltage device and manufacturing method thereof |
SG11201407534PA (en) | 2012-06-13 | 2014-12-30 | Hoffmann La Roche | New diazaspirocycloalkane and azaspirocycloalkane |
WO2014031170A1 (en) | 2012-08-22 | 2014-02-27 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
IN2015DN00960A (es) | 2012-09-25 | 2015-06-12 | Hoffmann La Roche | |
US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
CN104968656B (zh) | 2012-12-19 | 2017-08-11 | 诺华股份有限公司 | 自分泌运动因子抑制剂 |
TWI499591B (zh) | 2013-01-11 | 2015-09-11 | Lilly Co Eli | 雙環嘧啶化合物 |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
TR201808466T4 (tr) | 2013-11-05 | 2018-07-23 | Bayer Cropscience Ag | Artropodlarla mücadele için yeni bileşikler. |
MX2016006685A (es) | 2013-11-22 | 2016-09-08 | Basf Se | Compuestos heterociclicos de n-acilimino. |
BR112016010221A2 (pt) | 2013-11-22 | 2018-05-02 | Pharmakea Inc | inibidores tetracíclicos de autotaxina. |
CN105793253B (zh) | 2013-11-22 | 2019-08-23 | 法玛克亚公司 | 自分泌运动因子抑制剂化合物 |
CL2016001118A1 (es) | 2013-11-22 | 2016-12-02 | Basf Se | Compuestos heterocíclicos de n-acilimino |
US9051320B1 (en) * | 2014-08-18 | 2015-06-09 | Pharmakea, Inc. | Methods for the treatment of metabolic disorders by a selective small molecule autotaxin inhibitor |
AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
-
2014
- 2014-11-20 CN CN201480063881.XA patent/CN105793253B/zh active Active
- 2014-11-20 EP EP14864293.7A patent/EP3071561B1/en active Active
- 2014-11-20 BR BR112016010220-7A patent/BR112016010220B1/pt active IP Right Grant
- 2014-11-20 RS RS20210786A patent/RS62027B1/sr unknown
- 2014-11-20 CN CN201910686732.3A patent/CN110372671B/zh active Active
- 2014-11-20 EP EP21156420.8A patent/EP3878848A1/en active Pending
- 2014-11-20 KR KR1020227005531A patent/KR102515248B1/ko active IP Right Grant
- 2014-11-20 KR KR1020167014496A patent/KR102367876B1/ko active IP Right Grant
- 2014-11-20 SI SI201431843T patent/SI3071561T1/sl unknown
- 2014-11-20 WO PCT/US2014/066706 patent/WO2015077503A1/en active Application Filing
- 2014-11-20 CA CA2930737A patent/CA2930737C/en active Active
- 2014-11-20 ES ES14864293T patent/ES2875899T3/es active Active
- 2014-11-20 AU AU2014352888A patent/AU2014352888B2/en active Active
- 2014-11-20 EA EA201690881A patent/EA030068B1/ru unknown
- 2014-11-20 MX MX2016006623A patent/MX2016006623A/es active IP Right Grant
- 2014-11-20 MY MYPI2016000959A patent/MY182095A/en unknown
- 2014-11-20 PL PL14864293T patent/PL3071561T3/pl unknown
- 2014-11-20 PE PE2016000669A patent/PE20160654A1/es unknown
- 2014-11-20 PT PT148642937T patent/PT3071561T/pt unknown
- 2014-11-20 NZ NZ720478A patent/NZ720478A/en unknown
- 2014-11-20 CR CR20190394A patent/CR20190394A/es unknown
- 2014-11-20 DK DK14864293.7T patent/DK3071561T3/da active
- 2014-11-20 HU HUE14864293A patent/HUE055213T2/hu unknown
- 2014-11-20 CR CR20160289A patent/CR20160289A/es unknown
- 2014-11-20 LT LTEP14864293.7T patent/LT3071561T/lt unknown
- 2014-11-20 JP JP2016533532A patent/JP6501367B2/ja active Active
-
2015
- 2015-10-29 US US14/926,877 patent/US9334261B2/en active Active
-
2016
- 2016-03-03 US US15/060,398 patent/US9468628B2/en active Active
- 2016-05-02 IL IL24538316A patent/IL245383B/en active IP Right Grant
- 2016-05-09 ZA ZA2016/03083A patent/ZA201603083B/en unknown
- 2016-05-10 PH PH12016500862A patent/PH12016500862B1/en unknown
- 2016-05-20 NI NI201600071A patent/NI201600071A/es unknown
- 2016-05-20 MX MX2020009780A patent/MX2020009780A/es unknown
- 2016-05-20 CL CL2016001231A patent/CL2016001231A1/es unknown
- 2016-09-09 US US15/261,659 patent/US9999615B2/en active Active
- 2016-12-21 HK HK16114544A patent/HK1226075A1/zh unknown
-
2018
- 2018-05-03 US US15/970,337 patent/US10688081B2/en active Active
-
2019
- 2019-08-09 AU AU2019213425A patent/AU2019213425B2/en active Active
- 2019-10-24 IL IL270168A patent/IL270168B/en unknown
-
2020
- 2020-05-14 US US16/874,073 patent/US11344533B2/en active Active
- 2020-08-05 ZA ZA2020/05029A patent/ZA202005029B/en unknown
-
2021
- 2021-06-15 HR HRP20210957TT patent/HRP20210957T1/hr unknown
- 2021-06-23 CY CY20211100562T patent/CY1124407T1/el unknown
-
2022
- 2022-05-06 US US17/662,403 patent/US11779568B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2016001231A1 (es) | Compuestos de inhibidor de autotaxina | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
MX2015011898A (es) | Compuestos de pirazolo y usos de los mismos. | |
CL2014002873A1 (es) | Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer. | |
CL2015002658A1 (es) | Derivados de 2, 3 - disustituto 1- acil -4 amino - 1,2,3,4 tetrahidroquinilina y su uso como inhibidores de bromodominio | |
CL2015002472A1 (es) | Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4. | |
CL2015001985A1 (es) | Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim. | |
CL2012003415A1 (es) | Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer . | |
CL2016001131A1 (es) | Uso de una combinación farmacéutica que comprende un compuesto inhibidor de mdm2 y uno o más agentes activos adicionales para el tratamiento del cáncer y composiciones farmacéuticas que comprenden dichas combinaciones. | |
CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
BR112016020199A2 (pt) | Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
CL2015002932A1 (es) | Inhibidores de proteína quinasa | |
CL2015000829A1 (es) | Inhibidores de histona desmetilasas | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
EP4230264A3 (en) | Prodrugs of fumarates and their use in treating various deseases | |
CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
CL2015002897A1 (es) | Inhibidores de bace1 | |
CL2014001858A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas, antagonistas de mdm2; composicion farmacetica; y su uso en el tratamiento o profilaxis del cancer. |